News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major news articles were published in the past hour.
  • Global equity and bond markets had no new catalysts reported in the last hour.
  • No fresh central bank announcements or policy moves occurred in the past hour.
  • No significant corporate earnings or M&A headlines emerged in the last hour.
  • No major geopolitical developments or conflicts were reported during the past hour.
  • Economic indicators and market-moving data releases were absent in the past hour.

Latest Articles

SL Green’s 2026 Office Leasing Reaches Nearly 1.8 Million Square Feet

SL Green’s 2026 Office Leasing Reaches Nearly 1.8 Million Square Feet

SL Green Realty Corp., Manhattan’s largest office landlord, announced leasing of 1.76 million square feet of office space in 2026 so far, achieving a 15.8% increase in rents versus prior leases. The company also has over 1 million square feet in its current leasing pipeline, with several key tenants renewing or expanding leases, demonstrating stron…

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Beta Bionics announced FDA clearance for its innovative Mint patch pump and submitted its next-generation insulin dosing algorithm, 3D Intelligence, for FDA review. Full commercialization of Mint is expected in Q1 2027 with manufacturing capacity to produce at least 1.5 million units in 2027. 3D Intelligence aims to offer personalized insulin deliv…

American Battery Technology Company Reports FY 26 Financial Results, Delivering 407% Revenue Growth and Positive Adjusted Gross Profit

American Battery Technology Company Reports FY 26 Financial Results, Delivering 407% Revenue Growth and Positive Adjusted Gross Profit

American Battery Technology Company (NASDAQ: ABAT) announced its fiscal year 2026 financial results, delivering a 407% revenue increase to $21.7 million and achieving positive adjusted gross profit of $1.7 million. The company advanced its domestic lithium-ion battery recycling facilities, including ramping its first commercial-scale operation and …

Caliber Completes $3.4 Million Refinance of Corporate Notes and Secures the Right to Retire an Additional $9.1 Million at a Discount

Caliber Completes $3.4 Million Refinance of Corporate Notes and Secures the Right to Retire an Additional $9.1 Million at a Discount

Caliber, a real estate-focused alternative asset manager, has completed refinancing $3.4 million of its corporate notes with longer-term amortizing notes and converted $0.6 million into convertible preferred stock, reducing annual interest expenses. Furthermore, the company secured agreements allowing it to retire an additional $9.1 million of note…

Bowman Consulting Group Announces Expiration of “Go-Shop” Period

Bowman Consulting Group Announces Expiration of “Go-Shop” Period

Bowman Consulting Group has announced the expiration of the 'go-shop' period related to its planned acquisition by Bernhard Capital Partners. During this period, no competing bids emerged despite active solicitation, affirming Bernhard's all-cash offer of $43.00 per share, representing a 58% premium over the unaffected stock price. The acquisition …

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

BriaCell Therapeutics announced that the independent Data Safety Monitoring Board (DSMB) has recommended continuing the company's pivotal Phase 3 trial of Bria-IMT combined with an immune checkpoint inhibitor for metastatic breast cancer. This marks the seventh consecutive positive DSMB review, indicating no safety concerns and reinforcing the favo…

Materion Upgrade: Growth Is Showing Up — Time to Lean In

Materion Upgrade: Growth Is Showing Up — Time to Lean In

Materion (MTRN) has been grinding higher off last year's low as demand for advanced electronic and aerospace materials recovers. Fundamentals and technicals suggest upside to near-term targets, and the risk/reward looks favorable if you accept a modestly elevated valuation. Trade plan provided for a long-term swing into $300 with a $245 stop.

Edible Garden Showcases the Farm-to-Formula® Future of Clean Nutrition and Ready-to-Drink Innovation at ECRM

Edible Garden Showcases the Farm-to-Formula® Future of Clean Nutrition and Ready-to-Drink Innovation at ECRM

Edible Garden AG Inc., a Nasdaq-listed leader in controlled environment agriculture and sustainable produce, is showcasing its expanding clean nutrition and ready-to-drink (RTD) products at the ECRM Vitamin, Weight Management & Sports Nutrition session. The company is promoting its Farm-to-Formula® strategy, leveraging its traditional produce busin…

Hub Group Announces Select Preliminary First and Second Quarter 2026 Financial Results and Provides Update on Restatement Process

Hub Group Announces Select Preliminary First and Second Quarter 2026 Financial Results and Provides Update on Restatement Process

Hub Group, Inc. released preliminary unaudited financial results for the first half of 2026, highlighting revenue in line with expectations but operating losses due to increased costs and accounting restatement-related expenses. The company is undergoing an extensive financial statement restatement process, which has delayed SEC filings and led Nas…

Stryker: Oversold Setback Creates a Tactical Long Opportunity

Stryker: Oversold Setback Creates a Tactical Long Opportunity

Stryker's stock has been punished this month, pushing the shares to a 52-week low near $267. Oversold technicals, a healthy balance sheet, and $4.7B of trailing free cash flow suggest a mean-reversion trade. We'll lay out an entry, stop and target for a mid-term swing (45 trading days) while highlighting the key operational and macro risks that cou…

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Senseonics Holdings announces a strategic partnership with Beta Bionics to integrate its Eversense 365 year-long continuous glucose monitor with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system. The collaboration aims to commercialize a combined diabetes management solution by Q4 2026, offering enhanced ease and autonomy to pati…

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals announced positive topline data from its Phase 1b CANYON-1 study evaluating CRB-913 for obesity treatment. The oral CB1 inverse agonist showed statistically significant mean weight loss of 5% at 60 mg dosage after 12 weeks without weight loss plateau, and demonstrated a favorable safety and tolerability profile compared to or…

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio Inc. appointed R. Duane Clark II, a Sanofi rare-disease executive, and James Sapirstein, an experienced biopharma business development leader, to its Board of Directors. These appointments aim to bolster the company's commercialization planning for Ebstrocel™, a late-stage treatment targeting recessive dystrophic epidermolysis bullosa (R…

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

MediWound Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) recommends continuing the Phase III VALUE study of EscharEx for venous leg ulcers without any modifications, following a safety review. The company expects to complete enrollment by Q1 2027, reinforcing confidence in the drug's favorable safety profile and ongoing…

VisionWave Files U.S. Non-Provisional Patent Application Describing ARGUS™, a Proposed Space-Enabled, AI-Driven Counter-Drone Defense Architecture

VisionWave Files U.S. Non-Provisional Patent Application Describing ARGUS™, a Proposed Space-Enabled, AI-Driven Counter-Drone Defense Architecture

VisionWave Holdings, Inc. announced the filing of a U.S. non-provisional patent application describing ARGUS™, a proposed space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) architecture. ARGUS integrates satellite surveillance, AI-based object recognition, resilient communications, and layered defensive technologies to detect and cou…